Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPRA | P18433 | 1/20 | 0.34 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.31 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.31 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16452409 | 1.00 | PTPRA (0.34) | PTPRACYP1A2CYP2C9HIF1A | |
| SCHEMBL1312465 | 0.84 | PTPRA (0.50) | PTPRA | |
| SCHEMBL1312464 | 0.84 | PTPRA (0.50) | PTPRA | |
| SCHEMBL13201637 | 0.83 | PTPRA (0.33) | PTPRA | |
| SCHEMBL14640012 | 0.83 | PTPRA (0.33) | PTPRACYP1A2CYP2C9HIF1A | |
| SCHEMBL6865358 | 0.82 | MAP3K7 (0.30) | — | |
| SCHEMBL12568355 | 0.82 | MAP3K7 (0.30) | — | |
| SCHEMBL12202544 | 0.82 | MAP3K7 (0.30) | — | |
| Water SCHEMBL2000820 | 0.82 | PTPRA (0.49) | PTPRA | |
| Water SCHEMBL2000818 | 0.82 | PTPRA (0.49) | PTPRA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9452225-B2 | GLP-1 prodrugs | NOVO NORDISK A/S (DK) | 2016-09-27 | — | — | US | disclosed |
| US-9217022-B2 | GLP-1 receptor agonist compounds having stabilized regions | ASTRAZENECA PHARMACEUTICALS LP (US) | 2015-12-22 | — | — | US | disclosed |
| US-9072794-B2 | Long-acting glucagon conjugate and pharmaceutical composition comprising the same for the prevention and treatment of obesity | HANMI SCIENCE CO., LTD (KR) | 2015-07-07 | — | — | US | disclosed |
| US-20150045281-A1 | GLP-1 PRODRUGS | Novo Nordisk A/S a corporation | 2015-02-12 | — | — | US | disclosed |
| US-20130184203-A1 | GLP-1 RECEPTOR AGONIST COMPOUNDS HAVING STABILIZED REGIONS | ASTRAZENECA PHARMACEUTICALS LP (US) | 2013-07-18 | — | — | US | disclosed |
| US-8263084-B2 | Pharmaceutical composition for treating obesity-related disease comprising insulinotropic peptide conjugate | HANMI SCIENCE CO., LTD (KR) | 2012-09-11 | — | — | US | disclosed |
| US-7960349-B2 | N-terminally modified GLP-1 receptor modulators | BRISTOL-MYERS SQUIBB COMPANY (US) | 2011-06-14 | — | — | US | disclosed |
| US-7960349-B2 | N-terminally modified GLP-1 receptor modulators | BRISTOL-MYERS SQUIBB COMPANY (US) | 2011-06-14 | — | — | US | disclosed |
| US-20100330108-A1 | PHARMACEUTICAL COMPOSITION FOR TREATING OBESITY-RELATED DISEASE COMPRISING INSULINOTROPIC PEPTIDE CONJUGATE | HANMI PHARMACEUTICAL CO., LTD. (KR) | 2010-12-30 | — | — | US | disclosed |
| WO-2010120476-A2 | N-TERMINUS CONFORMATIONALLY CONSTRAINED GLP-1 RECEPTOR AGONIST COMPOUNDS | AMYLIN PHARMACEUTICALS, INC. (US) | 2010-10-21 | — | — | WO | disclosed |
| US-20080242593-A1 | HUMAN GLUCAGON-LIKE-PEPTIDE-1 MODULATORS AND THEIR USE IN THE TREATMENT OF DIABETES AND RELATED CONDITIONS | BRISTOL-MYERS SQUIBB COMPANY | 2008-10-02 | — | — | US | disclosed |
| US-7417028-B2 | Human glucagon-like-peptide-1 modulators and their use in treatment of diabetes and related conditions | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-08-26 | — | — | US | disclosed |
| US-7417028-B2 | Human glucagon-like-peptide-1 modulators and their use in treatment of diabetes and related conditions | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-08-26 | — | — | US | disclosed |
| US-20080045461-A1 | N-TERMINALLY MODIFIED GLP-1 RECEPTOR MODULATORS | BRISTOL-MYERS SQUIBB COMPANY | 2008-02-21 | — | — | US | disclosed |
| US-20080045461-A1 | N-TERMINALLY MODIFIED GLP-1 RECEPTOR MODULATORS | BRISTOL-MYERS SQUIBB COMPANY | 2008-02-21 | — | — | US | disclosed |
| US-20070099835-A1 | Sustained release GLP-1 receptor modulators | BRISTOL-MYERS SQUIBB COMPANY | 2007-05-03 | — | — | US | disclosed |
| US-20070099835-A1 | Sustained release GLP-1 receptor modulators | BRISTOL-MYERS SQUIBB COMPANY | 2007-05-03 | — | — | US | disclosed |
| US-20070021346-A1 | N-terminally modified GLP-1 receptor modulators | BRISTOL-MYERS SQUIBB COMPANY | 2007-01-25 | — | — | US | disclosed |
| US-20070021346-A1 | N-terminally modified GLP-1 receptor modulators | BRISTOL-MYERS SQUIBB COMPANY | 2007-01-25 | — | — | US | disclosed |
| WO-2006127948-A2 | N-TERMINALLY MODIFIED GLP-1 RECEPTOR MODULATORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2006-11-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070021346-A1 | N-terminally modified GLP-1 receptor modulators | GLP1R, GIPR, IAPP | PTPRA 1098/4885CYP1A2 4172/4885CYP2C9 3721/4885 |
| US-20130184203-A1 | GLP-1 RECEPTOR AGONIST COMPOUNDS HAVING STABILIZED REGIONS | GLP1R, GIPR, GCGR | PTPRA 2268/4885CYP1A2 4791/4885CYP2C9 4670/4885 |
| US-20080242593-A1 | HUMAN GLUCAGON-LIKE-PEPTIDE-1 MODULATORS AND THEIR USE IN THE TREATMENT OF DIABETES AND RELATED CONDITIONS | GLP1R, GIPR, IAPP | PTPRA 1295/4885CYP1A2 3175/4885CYP2C9 2816/4885 |
| US-20150045281-A1 | GLP-1 PRODRUGS | GLP1R, SLC5A1, DPP8 | PTPRA 3453/4885CYP1A2 349/4885CYP2C9 744/4885 |
| US-20080045461-A1 | N-TERMINALLY MODIFIED GLP-1 RECEPTOR MODULATORS | GLP1R, GIPR, IAPP | PTPRA 1082/4885CYP1A2 4191/4885CYP2C9 3779/4885 |
| US-20070099835-A1 | Sustained release GLP-1 receptor modulators | GLP1R, GIPR, GRPR | PTPRA 1025/4885CYP1A2 4204/4885CYP2C9 3181/4885 |
| US-20100330108-A1 | PHARMACEUTICAL COMPOSITION FOR TREATING OBESITY-RELATED DISEASE COMPRISING INSULINOTROPIC PEPTIDE CONJUGATE | GPR119, IAPP, GIPR | PTPRA 2117/4885CYP1A2 4289/4885CYP2C9 3466/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.